Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

被引：1

作者：

Nastoupil, Loretta J. ^{[1
]}

Andersen, Clark R. ^{[1
]}

Ayers, Amy ^{[1
]}

Wang, Yucai ^{[2
]}

Habermann, Thomas M. ^{[2
]}

Chihara, Dai ^{[1
]}

Kahl, Brad S. ^{[3
]}

Link, Brian K. ^{[4
]}

Cohen, Jonathon B. ^{[5
]}

Martin, Peter ^{[6
]}

Lossos, Izidore S. ^{[7
]}

Casulo, Carla ^{[8
]}

Lin, Ruitao ^{[1
]}

Li, Ziyi ^{[1
]}

Larson, Melissa C. ^{[2
]}

Maurer, Matthew J. ^{[2
]}

Huynh, Lynn ^{[9
]}

Gao, Chi ^{[9
]}

Ramasubramanian, Ramya ^{[9
]}

Sheng, Mei ^{[9
]}

Mutebi, Alex ^{[10
]}

Wang, Tongsheng ^{[10
]}

Jun, Monika ^{[10
]}

Wang, Anthony ^{[11
]}

Kamalakar, Rajesh ^{[11
]}

Kalsekar, Anupama ^{[10
]}

Cerhan, James R. ^{[2
]}

Flowers, Christopher R. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Mayo Clin, Rochester, MN USA

[3] Washington Univ, Sch Med St Louis, St Louis, MO USA

[4] Univ Iowa, Carver Coll Med, Iowa City, IA USA

[5] Emory Univ, Atlanta, GA USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Miami Hlth Syst, Miami, FL USA

[8] Univ Rochester, Med Ctr, Rochester, NY USA

[9] Anal Grp Inc, Boston, MA USA

[10] Genmab, Princeton, NJ USA

[11] AbbVie Inc, Chicago, IL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174497

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Cost-effectiveness of axicabtagene ciloleucel as second-line therapy for patients large b-cell lymphoma (lbcl) in the united states
Perales, M. -A.
Kuruvilla, J.
Snider, J. Thornton
Vadgama, S.
Blissett, R.
El-Moustaid, F.
Smith, N.
Patel, A.
Johnston, P.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 130 - 131
[22] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Hout, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin W.
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rong
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
[23] US COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL), CONSIDERING INFUSION SETTING AND PAYOR CLAIMS DATA
Joyner, Cummings A. K.
Snider, J.
Wade, S.
Wang, S. T.
Buessing, M. G.
Johnson, S.
Gergis, U.
VALUE IN HEALTH, 2022, 25 (07) : S405 - S405
[24] Efficacy and Safety of Lenalidomide, Rituximab Combined with Second-Line Chemotherapy (R2-chemo) in Patients with Relapsed/Refractory Diffuse Large-B Cell Lymphoma
Xiao, Fei
Huang, Honghui
Hua, Yanni
Fang, Yi
Zhang, Minyue
Hou, Jian
BLOOD, 2020, 136
[25] Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma
Tisi, Maria Chiara
Paolini, Rossella
Piazza, Francesco
Ravelli, Erika
Tecchio, Cristina
Sartori, Roberto
Famengo, Barbara
D'Amore, Emanuele Stefano Giovanni
Carli, Giuseppe
Perbellini, Omar
Di Bona, Eros
Ruggeri, Marco
Visco, Carlo
AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (12) : E386 - E389
[26] Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
Dickinson, Michael
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Trneny, Marek
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Balari, Anna Sureda
Perez-Callejo, David
Lundberg, Linda
Relf, James
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Phillips, Tycel
Thieblemont, Catherine
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Do, Young Rok
Feldman, Tatyana A.
Gasiorowski, Robin
Jurczak, Wojciech
Kim, Tae Min
Lewis, David John
van Der Poel, Marjolein
Poon, Michelle Limei
Kilavuz, Nurgul
Stirner, Mariana Cota
Soong, David
Chiu, Christopher
Chen, Menghui
Sacchi, Mariana
Elliot, Brian
Hutchings, Martin
Lugtenburg, Pieternella
BLOOD, 2022, 140 : 9443 - 9445
[28] Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Herrera, Alex F.
Chen, Lu
Crombie, Jennifer L.
Cohen, Jonathon B.
Advani, Ranjana H.
LaCasce, Ann S.
Popplewell, Leslie L.
Puverel, Sandrine
Peters, Lacolle
Daniels, Shari
Godfrey, James
Shouse, Geoffrey
Mei, Matthew
Kambhampati, Swetha
Budde, L. Elizabeth
Nikolaenko, Liana
Rosen, Steven T.
Kwak, Larry W.
Forman, Stephen J.
Matasar, Matthew J.
BLOOD, 2022, 140 : 1065 - 1067
[29] Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)
Dahiya, Saurabh
Spiegel, Jay Y.
Lee, Dasom
Mohammed, Turab
Lutfi, Forat
Goyal, Anmol
Hana, Caroline
Chavez, Julio C.
Ionescu, Filip
Frank, Matthew J.
Bharadwaj, Sushma
Sandoval-Sus, Jose
Beitinjaneh, Amer M.
Lekakis, Lazaros J.
McGuirk, Joseph P.
Locke, Frederick L.
Miklos, David B.
Jain, Michael D.
BLOOD, 2023, 142
[30] Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma
Kambhampati, Swetha
Saumoy, Monica
Schneider, Yecheskel
Serrao, Steve
Solaimani, Pejman
Budde, Lihua Elizabeth
Mei, Matthew G.
Popplewell, Leslie L.
Siddiqi, Tanya
Zain, Jasmine
Forman, Stephen J.
Kwak, Larry W.
Rosen, Steven T.
Danilov, V. Alexey
Herrera, Alex F.
Thiruvengadam, Nikhil R.
BLOOD, 2022, 140 (19) : 2024 - 2036

← 1 2 3 4 5 →